No Data
No Data
ITeos to Participate in Upcoming Investor Conferences
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46
Leerink Partners Maintains ITeos Therapeutics(ITOS.US) With Buy Rating
Strategic Catalysts and Financial Stability Underpin Buy Rating for ITeos Therapeutics
No Data
Gobinath OP :